gentamicin Flashcards
ahminoglycosides are primarily excreted …. so impairment has this consequence…
renally
so accumulation can occur in RI - increased risk of ototoxicity and nephrotoxicity
in which patients must you frequently monitor serum-amino glycoside conc
in pt with RI
monitoring of patients parameters (3)
assess renal function BEFORE starting and DURING treatment
monitor auditory and vestibular function DURING treatment
MHRA for all aminoglycosied by injection and when used by ear - increased risk of deafness in pt with mitochonridal mutations
- rare
- consider genetic testing esp in pt needing recurrent or long term treatment, however do not delay urgent treatment
- monitor renal and auditory function and hepatic and laboratory parameters to minimise risk of adverse effects
- pt with known mitochondrial mutations or FHx ototoxicity to inform Dr or pharmacist before using ahminoglycosides
there is an increased risk of ….. in pt with …. mutations
deafness with mitochondrial mutations (even if serum levels are within recommended range)
gentamicin MHRA advice about potential for histamine related adverse drug with IM, intrathecal or IV use
some batches of gentamicin sulphate API used to manufacture gentamicin may contain higher than expected levels of histamine (residual from manufacturing process)
monitor pt with signs of histamine related adverse reactions
particular caution required in pt taking concomitant drugs known to cause histamine release, in children and in pt with severe RI
some batches of gentamicin may contain higher than expected levels of histamine. thus you need to be aware of signs of histamine related adverse reactions e.g.
allergy symptoms
severe - anaphylaxis
some batches of gentamicin may contain higher than expected levels of histamine. thus you need to be aware of signs of histamine related adverse reactions. particular caution is requires in the following patients
patients taking concomitant drugs known to cause histamine release, in children, and in patients with severe renal impairment.
contraindications for all ahminoglycosides by injection and why
Myasthenia gravis (aminoglycosides may impair neuromuscular transmission)
why is it myasthenia gravis contraindicated for all aminoglycoses by injection
AG may impair neuromuscular transmission
whenever possible parenteral treatment should not exceed …
7days
what are two important side effects to consider with aminoglycoside therapy and who do they most commonly affect?
Ototoxicity and nephrotoxicity
Nephrotoxicity occurs most commonly in patients with renal impairment, who may require reduced doses; monitoring is particularly important in the elderly.
therapeutic drug monitoring of gentamicin with IM or IV use in adults. for multiple daily dose regimen, one hour peak serum conc should be ….. and pre-dose (trough) conc should be …..
one-hour (‘peak’) serum concentration should be 5–10 mg/litre;
pre-dose (‘trough’) concentration should be less than 2 mg/litre.
therapeutic drug monitoring of gentamicin with IM or IV use in adults. For multiple daily dose regimen in endocarditis, one-hour (‘peak’) serum concentration should be …. and pre dose (trough) conc should be ….
one-hour (‘peak’) serum concentration should be 3–5 mg/litre
pre-dose (‘trough’) concentration should be less than 1 mg/litre.
for multiple daily dose regimen in endocarditis, how often should you measure serum-gentamicin conc?
After 3 or 4 doses, then at least every 3 days and after a dose change (more frequently in renal impairment).